XML 39 R28.htm IDEA: XBRL DOCUMENT v3.19.1
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 03, 2018
USD ($)
Obligation
Oct. 31, 2018
USD ($)
Target
$ / shares
shares
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Apr. 30, 2019
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Proceeds from the issuance of common stock         $ 60,521,729 $ 56,585,035  
Revenues     $ 48,148,275 $ 650,125 82,806,171 $ 4,159,946  
Collaboration and License agreements              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial transaction price $ 226,300,000            
JJDC | Common Stock Purchase Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Shares issued | shares   3,260,869          
Stock issued, price per share | $ / shares   $ 23.00          
Janssen and JJDC              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenues     47,900,000   82,500,000    
Contract assets     13,300,000   13,300,000    
Contract liabilities     $ 120,600,000   120,600,000    
Janssen and JJDC | Common Stock Purchase Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Shares issued | shares   3,260,869          
Stock issued, price per share | $ / shares   $ 23.00          
Proceeds from the issuance of common stock   $ 75,000,000          
Janssen and JJDC | Collaboration and License agreements              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Proceeds from the issuance of common stock   75,000,000     75,000,000    
Cash received as due under collaboration agreement   175,000,000     $ 175,000,000    
Janssen              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Number of distinct performance obligations | Obligation 1            
Janssen | Common Stock Purchase Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 03, 2018            
Janssen | License Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 03, 2018            
Janssen | License Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development, regulatory and sales milestones payments   $ 1,600,000,000          
Janssen | Research Collaboration and Option Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 03, 2018            
Number of additional targets for development, regulatory and sales milestone payments | Target   3          
Janssen | Collaboration Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development, regulatory and sales milestones payments   $ 1,900,000,000          
Janssen | JNJ-3989 (ARO-HBV) Agreement | Subsequent Event              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payment             $ 25,000,000